Form 4: Pfizer CEO Bourla Acquires Phantom Stock Units
Insider Transaction
Pfizer Chairman & CEO Albert Bourla acquired 24 phantom stock units under a deferred compensation plan on May 15, 2026.
Summary
- Albert Bourla, Chairman & CEO of Pfizer Inc., acquired 24 phantom stock units on May 15, 2026.
- These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
- Each unit represents one phantom share of common stock.
- The units are settled in cash upon the reporting person's separation from service.
- Bourla can transfer these units into an alternative investment account at any time.
- Following this transaction, Bourla beneficially owns 773,297 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine executive compensation transaction rather than a significant strategic move or a reflection of immediate financial performance.
Positives
- The CEO's acquisition of phantom stock units indicates continued commitment and alignment with the company's long-term performance.
- The acquisition is part of a structured deferred compensation plan, suggesting a well-established executive compensation framework.
Future Outlook
The phantom stock units are settled in cash upon separation from service, with the possibility of transfer to an alternative investment account at any time by the reporting person.
Industry Context
StockSavvy.ai notes that insider transactions, such as this acquisition of phantom stock units by Pfizer's CEO, are common within the pharmaceutical industry as part of executive compensation and retention strategies. These actions often signal management's confidence in the company's future prospects.
Stakeholder Impact
- Shareholders: The transaction is a standard part of executive compensation and does not directly impact share price or immediate shareholder value, but it reflects management's ongoing engagement with the company.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Transaction date for the acquisition of phantom stock units. |
| 05/18/2026 | Date of report signature. |
Keywords
Pfizer, PFE, Form 4, Insider Trading, Executive Compensation, Phantom Stock Units, Deferred Compensation, Albert Bourla, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.